On July 1, 2020, Hua Medicine (Shanghai) Ltd. announced that the pivotal Phase III registration trial evaluating Dorzagliatin (HMS5552) efficacy and safety in Type 2 diabetes patients inadequately glycemic controlled with metformin in China HMM0302, met the primary efficacy and safety end point in the double-blinded placebo-controlled and randomized 24-week trial. Statistically significant improvements in HbA1c response rate, HOMA2-, HOMA2-IR, 2hPPG and FPG, were observed in the dorzagliatin-treated group over the placebo group.